Allup Silica Ltd

Aptose's Tuspetinib-Based Triple Therapy Shows Promise in Newly Diagnosed AML Patients

5 months ago

• Aptose Biosciences' TUSCANY trial evaluates tuspetinib (TUS) with venetoclax (VEN) and azacitidine (AZA) for newly diagnosed AML patients. • Early data from the trial's first cohort show complete remissions in patients with TP53 mutations and FLT3-wildtype AML. • The triplet therapy demonstrates a favorable safety profile, with no dose-limiting toxicities or prolonged myelosuppression observed. • The Cohort Safety Review Committee (CSRC) has approved dose escalation to 80 mg of tuspetinib based on the encouraging safety data.

Aptose and NCI Partner to Advance Tuspetinib in AML and MDS Trials

6 months ago

• Aptose Biosciences and the National Cancer Institute (NCI) have entered a CRADA to develop tuspetinib for AML and MDS. • Tuspetinib will be evaluated in NCI's myeloMATCH trials, focusing on targeted drug combinations for molecularly defined AML and MDS. • Aptose is also developing tuspetinib in a triple combination therapy for newly diagnosed AML patients unfit for chemotherapy. • The Phase 1/2 TUSCANY study of tuspetinib with venetoclax and azacitidine is on track to commence in Q4.

Aptose Biosciences' Tuspetinib Shows Promise in AML Triplet Therapy, Receives $10M Loan from Hanmi

7 months ago

• Aptose Biosciences received a $10 million loan from Hanmi Pharmaceutical to support the clinical development of tuspetinib, an oral kinase inhibitor. • Tuspetinib demonstrates broad clinical activity in AML patients with diverse mutation profiles, showing potential as a third agent in triplet therapy. • Aptose plans to initiate a triplet combination study of tuspetinib with venetoclax and a hypomethylating agent in newly diagnosed AML patients. • The company is addressing Nasdaq compliance issues while advancing tuspetinib's development, with multiple data readouts expected in 2024 and 2025.